mindpeak

Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI

Clinical Performance Evaluation Summary

Authors: Dr. Khalid Daifalla, Dr. Stefan Günther
Contact: info@mindpeak.ai

Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI supports pathologists in scoring of digital images of formalin-fixed, paraffin-embedded primary non-small cell lung cancer (NSCLC) tissue lesions from human lung cancer patients, which underwent immunohistochemistry (IHC) staining of the transmembrane protein programmed death-ligand 1 (PD-L1).

The clinical performance of Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI was evaluated with a heterogenous set of clinical routine cases from multiple institutions. Participating pathologists from different institutions assessed samples with real-life image variability introduced by multiple whole-slide image scanners and samples of different scoring groups.

The statistical evaluation shows that the output of Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI is clinically relevant ($p<0.05$): agreement rates when scoring with the assistance of Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI are larger than when scoring conventionally (Fig. 1). Additional results show that this result is agnostic to individual sample preparation parameters such as scanners and laboratory protocols.

More detailed information is available upon request via e-mail to info@mindpeak.ai.



Figure 1. *Agreement rates for conventional manual assessment and assessment with the support of Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI. Error bars indicate 95% confidence intervals.*